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South Indian populationAbstract Coronary artery disease (CAD) also known as coronary heart disease is one of the lead-
ing causes of death and disability worldwide. Genetic and environmental factors play an important
role in the pathogenesis and progression of CAD. The aim of this study was to evaluate the com-
bined contribution of 3 gene polymorphisms to the risk of CAD and gene–gene interaction in the
south Indian population. In this case-control study, 200 cases of CAD and 200 healthy controls
were recruited. We studied 3 well known genetic polymorphisms of MTHFR (C677T;
rs1801133), PON1 (Q192R; rs662) and ACE (I/D: rs4646994) in relation to CAD in South Indian
population. Polymerase chain reaction (PCR) was carried out and followed by the restriction frag-
ment length polymorphism and agarose gel electrophoresis. Genotypes ofMTHFR C677T, CT and
CT+TT, and PON1 Q192R QR were associated with the risk of CAD (C677T CT+TT vs CC:
odds ratio [OR] = 3.3, 95% conﬁdence intervals [CI] = 1.8–6.2; p= 0.00001), (CT vs CC:
OR = 3.2, 95%CI = 1.8–5.6; p= 0.00003), and (Q192R QQ vs QR: OR= 2.1, 95%CI = 1.1–
3.9; p= 0.03). The allele frequencies for T vs C: OR= 3.1, 95%CI = 1.8–5.3; p= 0.00001 and
R vs Q: OR = 1.3, 95% CI = 1.0–1.7 p= 0.03. Multifactor dimensionality reduction (MDR)
144 K. Matam et al.analysis was carried out with the combination of three genes and the results indicate that MDR
analysis showed that, PON1 gene polymorphism formed a signiﬁcant model in predicting the
CAD risk in south Indian population.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Atherosclerosis plays a key role in the pathogenesis of coro-
nary artery disease (CAD), a leading cause of death, account-
ing for approximately 30% of deaths worldwide and has
become a priority health problem in India. Currently, genetic
and environmental factors play an important role in the path-
ogenesis and progression of CAD (Liu et al., 2014; Ahmed,
2012). Clinical manifestations of CAD comprise a host of
acute and chronic conditions such as stable angina, acute cor-
onary syndromes and heart failure. Various lines of evidence
have suggested that genetic factors contribute signiﬁcantly to
the risk of CAD (Liu and Qiu, 2013) as conventional risk fac-
tors are insufﬁcient to explain the etiology of CAD in all cases
(Vijaya Lakshmi et al., 2011). The formation of athermanous
plaques and plaque rupture that leads to thrombotic occlusion
of the coronary arteries that are multifactorial with multiple
processes contributes to this pathologic cascade. These include
inﬂammation, lipid disorders, renin angiotensin system,
diabetic vasculopathy, hyperhomocysteinemia and others.
Genetic epidemiologic studies have suggested certain genetic
variants, including polymorphisms in the genes like methylene-
tetrahydrofolate reductase (MTHFR), paraoxonase1 (PON1)
and angiotensin converting enzyme (ACE) genes to have a
strong association with CAD and related outcomes.
MTHFR is one of the metabolic pathways for CAD and is
a key regulatory gene of the remethylation pathway. The
C677T polymorphism (rs1801133) in MTHFR has been impli-
cated in vascular disease (Masud and Qureshi, 2011).MTHFR
catalyzes the conversion of 50, 100-methylenetetrahydrofolate
reductase to 50-methylenetetrahydrofolate reductase, the major
circulating form of folate, which is required for a number of
metabolic pathways, including the methylation of homocyste-
ine to methionine (Wang et al., 2013). Individuals with C677T
polymorphism (rs1801133) have reducedMTHFR activity and
elevated homocysteine levels, which is associated with CAD
(Danesh and Lewington, 1998).Controversy exists regarding
the association of C677T polymorphism and CAD (Klerk
et al., 2002; Lewis et al., 2005). Human PON1 is a calcium-
dependent glycoprotein that is synthesized in the liver and
secreted into the plasma associated with high density lipopro-
teins. PON1 prevents LDL lipid peroxidation and protects
against atherosclerosis and coded by the HUMPONA, located
on 7q 21.3, along with two adjacent genes, PON2 and PON3
(Macharia et al., 2012). The Q192R (rs662) polymorphism in
the coding region of PON1 gene is an amino acid exchange
from glutamine (Q) to arginine (R) in the A575G region and
is associated with variation in its hydrolysis activity
(Macharia et al., 2012). PON1 activity has been consistently
reported to be signiﬁcantly diminished in atherosclerosis and
other cardiovascular diseases (Mohamed et al., 2013;
Agrawal et al., 2009). ACE gene is present on the surface of
vascular endothelial cells, generates the potent vasoconstrictorangiotensin II from angiotensin I and inactivates the vasodila-
tor bradykinin. Angiotensin II modulates NO synthesis in
cardiovascular tissue, and NO modulates the action of angio-
tensin II (Abdelhedi et al., 2013). A polymorphic variant in
intron 16 (ACE-I/D) of the ACE gene, characterized by an
insertion (I) or deletion (D) of a repeat sequence of 287 non-
coding base pairs (Zintzaras et al., 2008), has been shown to
be associated with hypertension and other cardiovascular risk
factors (Abdelhedi et al., 2013). The aim of the present case-
control study was to examine the association of C677T
MTHFR, A575G PON1 and ACE I/D polymorphisms individ-
ually and in combination with coronary artery disease in South
Indian population.
2. Materials and methods
2.1. Study design
This is a case-control study carried out on 400 subjects from
South India region. The study cohort consists of 200 patients
with documented CAD and 200 unrelated healthy control
subjects. The cases were recruited between January 2007 and
January 2012 from the patients, who visited Kamineni
hospitals in Hyderabad/Telangana region. Healthy controls
(n= 200) were recruited from the general population without
any complications.
2.2. Angiographic assessment and participant recruitment
All patients were admitted with acute coronary syndrome and
underwent coronary angiogram (CAG). Patients with P70%
stenosis in one or more coronary arteries were considered to
have CAD. Our study recruited 200 patients with age ranging
from 50 to 70 years who have triple vessel disease and under-
went coronary artery bypass graft surgery (CABG). We
excluded patients with septicemia, liver cirrhosis, renal failure,
colitis, cardiomyopathy, congenital heart disease, rheumatic
heart disease, neurological and cancer problems.
The control group consisted of 200 (139 males and 61
females) age and gender-matched healthy subjects from the
same region, and with prior normal lipid proﬁle. Clinical data
were obtained from all patients using a standard case report
form (CRF). Our study complied with the Declaration of
Helsinki and was approved by the institutional review board,
Kamineni hospitals, Hyderabad and informed consent was
obtained from all the patients and controls.
2.3. Anthropometric measurements
Body mass index (BMI) was calculated as weight in kg and
height in m2 (kg/m2). Height was measured using a wall-
mounted stadiometer, and body weight was measured using
a digital scale. BMI of each subject was calculated.
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Peripheral blood (5 mL) was collected from all the patients and
controls (n= 400) in EDTA tubes. The collected blood was
divided into two portions; 2 mL for DNA extraction and
molecular analysis and 3 mL for lipid proﬁle in biochemical
analysis.
2.5. Lipid proﬁle
Serum sample was collected in the plain tube to measure the
total cholesterol (TC), triglycerides (TG), high density lipopro-
tein cholesterol (HDL-C), low density lipoprotein cholesterol
(LDL-C) and very low density lipoprotein cholesterol
(VLDL-C) by using commercially available kits.
2.6. Molecular analysis
Genomic DNA was extracted using the conventional salting
out extraction method (Khan et al., 2013) and quantiﬁed by
using NanoDrop 2000 (Thermo Fisher Scientiﬁc, MA, USA).
2.7. Primers
Genotyping for MTHFR (rs1801133) and PON1 (rs662) was
performed by polymerase chain reaction (PCR) and restriction
fragment length polymorphism (RFLP). ACE (rs4646994) I/D
polymorphism was screened by direct PCR ampliﬁcation. The
details of the primers and PCR products are documented in
Table 1. Successful ampliﬁcation was conﬁrmed by electropho-
resis on an ethidium bromide impregnated 2% agarose gel.
PCR reactions were performed in a thermal cycler with an ini-
tial denaturation at 95 C for 5 min followed by 35 ampliﬁca-
tion cycles with each cycle consisting of denaturation at 95 C
for 30 s, 68 C for rs1801133 (MTHFR gene) polymorphism
(50 C for rs662 polymorphism in PON1 gene and 59 C for
ACE gene) and 30 s, 72 C for 45 s and the ﬁnal extension with
72 C for 5 min. PCR products were digested for 2 h with Hin-
fI forMTHFR gene (Fermentas, USA) at 37 C (2.5 lL of dis-
tilled water with 10 units of enzyme for 15 lL PCR product
and 2 lL buffer in a ﬁnal volume of 20 lL). For PON1 gene,
PCR products were digested for 16 h with AlwI (Fermentas,
USA) at 37 C (2.5 lL of distilled water with 10 units of
enzyme for 15 lL PCR product and 2 lL buffer in a ﬁnal vol-
ume of 20 lL).
2.8. Statistical analysis
Data were analyzed using the statistical software for windows
(SPSS version 19.0, Chicago, IL, USA) and are represented as
mean ± standard deviation (SD). Differences in baseline char-
acteristics between CAD patients and healthy subjects were
assessed by v2 test for categorical variables and independent
sample t-test was used to test for continuous variables. Allele
and genotype frequency differences between patients and sub-
jects were tested for each SNP using a chi-square test. Odds
ratios (ORs) and 95% conﬁdence intervals were calculated
by multinomial logistic regression for the allele and genotype
frequencies. A p value < 0.05 was considered statistically sig-
niﬁcant. Multifactor dimensionality reduction (MDR) analysis
was carried out with the selected genes to ﬁnd the correlation.
Figure 1 Lipid proﬁle for CAD and control male subjects.
T.CHOL – Total Cholesterol; TGL – Triglycerides; LDL – Low
Density Lipoprotein Cholesterol; HDL – High Density Lipopro-
tein Cholesterol and VLDL – Very Low Density Lipoprotein
Table 2 Demographic details involved in this study.
Proﬁle Cases (n= 200) Healthy controls (n= 200) p-Value
Age (mean ± SD) 56.4 ± 2.6 55.4 ± 2.8 p= 0.29
Sex (Male: Female) 140:60 136:64 p= 0.36
BMI (kg/m2) 27.2 ± 3.6 26.3 ± 3.4 p= 0.42
Hypertension 88 (44%) 12 (6%) p< 0.0001
Diabetes 90 (45%) 0 (0) p< 0.0001
Smoking 65 (32.5%) 21 (10.5%) p< 0.0001
Alcoholism 42 (21%) 18 (9%) p< 0.0001
Family history of MI 48 (24%) 0 (0) p< 0.0001
TC (mg/dL) 235.0 ± 13.7 162.9 ± 16.2 p< 0.0001
TG (mg/dL) 173.5 ± 12.5 135.1 ± 10.5 p< 0.0001
HDL-C (mg/dL) 33.1 ± 4.2 38.3 ± 5.4 p< 0.0001
LDL-C (mg/dL) 167.5 ± 14.5 93.7 ± 17.9 p< 0.0001
VLDL (mg/dL) 34.2 ± 2.5 26.8 ± 2.0 p< 0.0001
146 K. Matam et al.3. Results
3.1. Characteristics of the study group
Clinical and baseline characteristics of CAD patients and
healthy controls are shown in Table 2. The mean age of the
CAD patients and the controls was similar. The mean age
was not different between the two groups and was
56.4 ± 2.6 for the patients and 55.4 ± 2.8 for the controls.
Male formed 70% of the patients and 68% of the control
group. There was no age difference between males and females
in the two groups. Rate of risk factors for CAD was markedly
higher in the patient group; diabetes 45% vs 0% (p< 0.0001),
hypertension 44% vs 6% (p< 0.0001), smoking 32.5% vs
10.5% (p< 0.0001) and family history of CAD 24% vs 0%
(p< 0.0001). Lipid proﬁle analysis showed signiﬁcantly higher
TC, TG, LDL-C and VLDL-C and lower HDL-C in patients
compared to control subjects (p< 0.0001) (Figs. 1 and 2,
Table 2).Cholesterol.
Figure 2 Lipid proﬁle for CAD and control female subjects.
T.CHOL – Total Cholesterol; TGL – Triglycerides; LDL – Low
Density Lipoprotein Cholesterol; HDL – High Density Lipopro-
tein Cholesterol and VLDL – Very Low Density Lipoprotein
Cholesterol.3.2. Genotype frequencies
The genotype distribution of the three variants was in Hardy–
Weinberg equilibrium in both groups. The genotype and allele
distribution of MTHFR (rs1801133), PON1 (rs662) and ACE
(rs4646994) variants are summarized in Table 3. There was a
statistically signiﬁcant difference in the genotype distribution
in the rs1801133 polymorphism between the patients and con-
trols (p= 0.00003). Similarly, the allele frequencies were sig-
niﬁcantly different (p= 0.00001). The risk of developing the
disease was found to be 3.1-fold for T allele carriers, signifying
a potential association. The genotype frequency for PON1
(rs662) polymorphism was also found to be signiﬁcantly differ-
ent between the patients and controls with more prevalent GG
(p= 0.01), and AA+GG (p= 0.01) genotypes, and the G
(p= 0.03) allele of rs662 polymorphisms in CAD patients.
Our results could not ﬁnd a signiﬁcant association between
ACE I/D polymorphism and CAD in our study population.
Table 4 represents the genotype and allele distribution of
MTHFR (rs1801133), PON1 (rs662) and ACE (rs4646994)
variants based on gender. In male subjects, the odds ratios
for having CAD with T allele and CT genotype in MTHFR
were 3.4 (CI = 1.2–9.7, p= 0.00008) and 2.7 (CI = 1.4–5.3,
Table 4 Genotypic distribution of C677T, A575G and I/D polymorphisms in male and female individuals.
Genotype/allele CAD
N (%)
Healthy controls
N (%)
Odds ratio (95% CI) p-Value
Males Females Males Females Males Females Males Females
677CﬁT
CC 102 (73.9) 46 (74.2) 124 (89.2) 56 (91.8) Reference Reference Reference Reference
CT 34 (24.7) 16 (25.8) 15 (10.8) 5 (8.2) 2.7 (1.4, 5.3) 3.8 (1.3, 11.4) 0.002 0.009
TT 2 (1.4) 0 (0) 0(0) 0 (0) 6.0 (0.2, 127.9) 1.2 (0.02, 62.5) 0.18 0.92
CT+TT 36 (26.1) 16 (25.8) 15 (10.8) 5 (8.2) 2.9 (1.5, 5.6) 3.8 (1.3, 11.4) 0.001 0.009
C 238 (0.86) 108 (0.87) 263 (0.95) 117 (0.96) Reference Reference Reference Reference
T 38 (0.14) 16 (0.13) 15 (0.05) 5 (0.04) 2.7 (1.5, 5.2) 3.4 (1.2, 9.7) 0.0008 0.01
192QﬁR
AA 35 (25.4) 21 (33.9) 45 (32.4) 22 (36) Reference Reference Reference Reference
AG 70 (50.7) 33 (53.2) 78 (56.1) 32 (52.5) 1.1 (0.6, 1.9) 1.0 (0.4, 2.3) 0.6 0.8
GG 33 (23.9) 8 (12.9) 16 (11.5) 7 (11.5) 2.6 (1.2, 5.5) 1.1 (0.3, 3.8) 0.009 0.7
AG+GG 103 (74.6) 41 (66.1) 94 (67.6) 39 (64) 1.4 (0.8, 2.3) 1.1 (0.5, 2.3) 0.19 0.7
A 140 (0.51) 75 (0.60) 168 (0.60) 76 (0.62) Reference Reference Reference Reference
G 136 (0.51) 49 (0.40) 110 (0.40) 46 (0.38) 1.4 (1.0, 2.0) 1.0 (0.6, 1.8) 0.02 0.7
IﬁD
II 45 (32.6) 20 (32.3) 40 (28.8) 20 (32.8) Reference Reference Reference Reference
ID 61 (44.2) 30 (48.4) 75 (53.9) 30 (49.2) 0.7 (0.4, 1.2) 1 (0.4, 2.2) 0.2 1
DD 32 (23.2) 12 (19.3) 24 (17.3) 11 (18) 1.1 (0.6, 2.3) 1.0 (0.3, 3.0) 0.6 0.8
ID+DD 93 (67.4) 42 (67.7) 99 (71.2) 41 (67.2) 0.8 (0.5, 1.3) 1.0 (0.4, 2.1) 0.4 0.9
I 151 (0.55) 70 (0.56) 155 (0.56) 70 (0.57) Reference Reference Reference Reference
D 125 (0.45) 54 (0.44) 123 (0.44) 52 (0.43) 1.0 (0.7, 1.4) 1.0 (0.6, 1.7) 0.8 0.8
Table 3 Genotype distribution of C677T, A575G and I28005D polymorphisms in the individuals with CAD and controls enrolled in
the South Indian population.
SNP Genotype/allele CAD patients (n= 200) Healthy controls (n= 200) Odds ratio (95%CI) p-Value
677CﬁT
CC 148 (74%) 181 (90.5%)
CT 50 (25%) 19 (9.5%) 3.2 (1.8, 5.6) 0.00003
TT 2 (1%) 0 (0) 0.1 (0.04, 0.5) 0.002*
CT+TT 52 (26%) 19 (9.5%) 3.3 (1.8, 6.2) 0.00001
C 346 (0.87) 381 (0.95)
T 54 (0.13) 19 (0.05) 3.1 (1.8, 5.3) 0.00001
192QﬁR
QQ 56 (28%) 67 (33.5%)
QR 103 (51.5%) 110 (55%) 1.1 (0.7, 1.7) 0.61
RR 41 (20.5%) 23 (11.5%) 2.1 (1.1, 3.9) 0.01
QR+RR 144 (72%) 133 (66.5%) 1.2 (0.8, 1.9) 0.23
Q 215 (0.54) 244 (0.61)
R 185 (0.46) 156 (0.39) 1.3 (1.0, 1.7) 0.03
IﬁD
II 65 (32.5%) 60 (30%)
ID 91 (45.5%) 105 (52.5%) 0.8 (0.5, 1.2) 0.33
DD 44 (22%) 35 (17.5%) 1.1 (0.6, 2.1) 0.60
ID+DD 135 (67.5%) 140 (70%) 0.8 (0.5, 1.3) 0.58
I 221 (0.55) 225 (0.56)
D 179 (0.45) 175 (0.44) 1.0 (0.7, 1.3) 0.77
Bold values indicates the signiﬁcantly associated when we perform the odds ratio.
* Indicates Yates correction.
Gene–gene interaction with coronary artery disease in South Indian population 147p= 0.002), and with G allele and AG genotype of PON1 1.4
(CI = 1.0–2.0, p= 0.02) and 2.6 (CI = 1.2–5.5, p= 0.009).
While in female subjects only the T allele and CT genotype
in MTHFR were associated with CAD [OR 3.4 (CI = 1.2–9.7); p= 0.001] and [OR 3.8 (CI = 1.3–11.4); p= 0.009].
Power analysis revealed that power of 76% can be achieved
by genotyping only 24% of the total number of samples used
in our study.
Figure 3 Serum homocysteine levels of MTHFR genotypes in
CAD patients.
Figure 5 Radial graphic representation of interaction of ACE,
MTHFR, PON1 genes by MDR analysis.
148 K. Matam et al.3.3. Correlation of MTHFR genotypes with serum homocysteine
levels (SHL)
Forty two patients exhibited CC genotype while 45 had CT
genotype and 2 were TT genotype patients. The Mean ± SD
of SHL for CC genotype was 12.95 ± 1.83 lmol/L, for CT
genotype 19.34 ± 3.13 lmol/L, for TT genotype 27 ±
1.41 lmol/L. The comparisons of SHL levels with the geno-
types in patients are presented in Fig. 3. The levels of SHL were
abnormal in both TT and CT genotype patients and were
within normal limits in CC genotype patients. Furthermore,
SHL were higher in the TT than CT genotype patients. These
results indicate that C677T polymorphism might possibly be
associated with increased homocysteine levels and may there-
fore inﬂuence individual susceptibility to CAD.
3.4. Interaction of nuclear genes by MDR analysis
The effect of interaction of three nuclear genes are analyzed in
the pathogenesis of CAD by MDR. The list of attributes
included three genes (ACE, MTHFR and PON1). All attri-
butes in these datasets are categorical. Graphical representa-
tion of MDR is shown in Fig. 4. By MDR model analysis
MTHFR can be used as a disease marker because of its high
sensitivity value. Further radial graphic representation byFigure 4 Interaction of MTHFR, PON1 and ACE genes between cMDR analysis was carried out between three genes and the
interaction appears to be between PON1 and ACE (Fig. 5).
4. Discussion
We have carried out a case-control study involving 200 cases
and 200 controls with CAD in south Indian population. Thus,
two of three studied polymorphisms of the MTHFR and
PON1 genes were signiﬁcantly associated with the risk of
CAD. Both the alleles and genotypes were found to be signif-
icantly associated. This study shows lack of association with
ACE I/D polymorphism but in combination of MDR analysis
it is associated with the combination of PON1 and ACE gene,
with CAD, is a complex disease with the contribution of multi-
ple genetic and environmental risk factors. A number of stud-
ies on the impact of genetic polymorphism in ACE on the risk
of coronary heart disease (CHD) have been conducted in var-
ious ethnic populations (O’Malley et al., 1999; Oei et al., 2005).
In this study, no signiﬁcant difference was observed in the dis-
tribution of genotype of ACE in CAD cases and controls. This
conﬁrms previous ﬁnding of Lindpaintner et al. (1995), Sobti
et al. (2010) and Pandey et al. (2011). The other studies carried
out on ACE and CHD risk among Indians have shown associ-
ation of D allele with the risk of CHD (Ashavaid et al., 2002;
Mishra et al., 2012; Dhar et al., 2012). The present results have
shown the susceptible effect of polymorphism in ACE on CADases and controls by MDR analysis by graphical representation.
Gene–gene interaction with coronary artery disease in South Indian population 149among south Indians to be involved with factors like smoking,
alcohol, diabetes and hypertension.
Diabetes and dyslipidemia are two major risk factors for
CAD, which are associated with oxidative stress (Ganesan
et al., 2011). The analysis of PON1 192 QR polymorphism
has revealed that the high 10 activity allele (R) is associated
with a more atherogenic lipid proﬁle than the low-activity
allele (Q). In this study, PON1 192R allele frequency in
CAD patients was found to be higher when compared with
the controls (p= 0.03). RR genotype was found to be associ-
ated with two fold increase in the risk of CAD development. In
our earlier study PON1 gene was proposed to be a candidate
biomarker for T2DM and CAD patients (Ganesan et al.,
2011). The present study investigated the role of this polymor-
phism in the development of CAD. The frequencies of the
genotypes and alleles were signiﬁcantly higher in patients com-
pared with controls, indicating the association of PON1 gene
Q192R polymorphism with the disease in both the formats
(i.e., gene association study and the MDR analysis). The
results of the present study were in accordance with observa-
tions of earlier investigators, which support that RR genotype
is associated with CAD (Ahmed, 2012; Ganesan et al., 2011;
Hassan et al., 2013).
MDR analysis was performed to interact the MTHFR,
PON1 and ACE genes by the pathogenesis of CAD. Our study
concludes that, PON1 can be used as a disease marker because
of its high sensitivity value. ACE alone does not play any role
in the disease risk but PON1 and ACE interaction increase the
risk by 3.08%. There is a negative interaction between PON1
and MTHFR genes, but MTHFR alone has a risk of 3.70%.
MDR analysis reveals that in overall entropy (randomness of
disorder) MTHFR is showing 3.70%, PON1 is showing
1.14% and ACE is showing 0.4% which is negligible indicating
MTHFR and PON1 are showing a major effect. Our study
indicated that gene–gene interaction showed a signiﬁcant
model in predicting the CAD risk.
The signiﬁcance of homozygous polymorphisms considered
to be risk factors for CAD when analyzed: MTHFR and
PON1. The genotypes with statistically signiﬁcant higher fre-
quencies in the CAD patients were MTHFR and PON1.
Unlike many other studies, our analysis was not limited to
examining whether a single polymorphism presents increased
risk, but evaluated various polymorphisms and some of the
most important gene–gene associations, some of them never
studied before (Mendonca et al., 2009). Sanghera et al.
(1997), Sanghera et al. (1998) reported that the PON1-192*R
allele is a risk factor for CHD among Asian Indians in Singa-
pore. Pati and Pati (1998) reported a higher frequency of the
QR and RR genotypes among Indian CAD patients.
We believe that the methodology used in this study was
appropriate and that our results may contribute to under-
standing the far from simple genetic aspects of complex and
multifactorial diseases such as CAD. Our results suggest that
the association of polymorphisms in the same gene does not
increase the risk of the isolated polymorphism, but that the
association of polymorphisms in genes belonging to different
enzyme systems is linked to increased risk compared to the iso-
lated polymorphisms. The study may explain the difﬁculty of
interpreting the risk of different polymorphisms in CAD,
and may open up new possibilities in this ﬁeld.
In conclusion, our results suggest that the D allele of the
ACE (rs4646994) may not be associated, whereas T allele ofMTHFR (rs1801133) and R allele of PON1 (rs662) gene poly-
morphisms were associated with an increased risk of CAD in
south Indian population. Our data strongly suggest that
PON1 gene is associated with genotype analysis as well as in
the combination of MDR analysis.
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